检索结果-南通市图书馆

Three-dimensional visualization and virtual reality simulation role in hepatic surgery:Further research warranted

World Journal of Gastrointestinal Surgery 2022年第7期14卷 723-726页

作者： Faiza Ahmed Vinay Jahagirdar Sravya Gudapati mohamad mouchli Division of Clinical and Translational Research Larkin Community HospitalSouth MiamiFL 33143United States Department of Internal Medicine University of Missouri Kansas City School of MedicineKansas CityMO 64108United States Department of Gastroenterology The Illinois Center for Digestive and Liver HealthChicagoIL 60660United States Department of Gastroenterology Cleveland ClinicClevelandOH 44195United States

Artificial intelligence(AI)is the study of algorithms that enable machines to analyze and execute cognitive activities including problem solving,object and word recognition,reduce the inevitable errors to improve the diagnostic accuracy,and *** procedures are technically complex and the use of AI in perioperative management can improve patient outcomes as discussed ***-dimensional(3D)reconstruction of images obtained via ultrasound,computed tomography scan or magnetic resonance imaging,can help surgeons better visualize the surgical sites with added depth *** 3D planning is associated with lesser operative time and intraoperative ***,a more accurate assessment is noted,which leads to fewer operative *** can be converted into physical models with 3D printing technology,which can be of educational value to students and trainees.3D images can be combined to provide 3D visualization,which is used for preoperative navigation,allowing for more precise localization of tumors and ***,AI enables surgeons to provide better,personalized care for each patient.

关键词： Artificial intelligence Three-dimensional printing Liver surgery Virtual reality Preoperative planning Simulation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma?

引用

World Journal of Gastrointestinal Surgery 2022年第8期14卷 862-866页

作者： Faiza Ahmed Faiza Zakaria Godsgift Enebong Nya mohamad mouchli Division of Clinical and Translational Research Larkin Community Hospital-Larkin Healthcare SystemsSouth MiamiFL 33143United States Department of Internal Medicine Dow Medical CollegeKarachi 75400Pakistan Department of Gastroenterology John Hopkins HospitalBaltimoreMD 21218United States Department of Gastroenterology Cleveland ClinicClevelandOH 44195United States

Liver transplantation(LT) withstands as the most preferred therapeutic option for patients afflicted with hepatocellular carcinoma(HCC) and cirrhosis. To improve prognosis post-transplant, as well as to prevent the occurrence of rejection, a lifelong immunosuppression strategy is implemented. The following letter to the editor highlights and provides novel evidence from recently published literature on topics discussed within the review article titled “Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma” in World J Gastrointest Surg 2021;13: 953-966. In the recent manuscript, the authors compared immunosuppressive drugs such as the newer option first-generation mammalian target of rapamycin inhibitor, also known as sirolimus, with the most widely used first-generation calcineurin inhibitors, such as tacrolimus(TAC). TAC is commonly known as the most effective immunosuppressive drug after LT, but it has been reported to cause intolerable side effects such as nephrotoxicity,neurotoxicity, diabetes, hypertension, gastrointestinal disturbances, increased risk of infections, and malignancies. It is necessary for physicians to be aware of recent advances in tacrolimus and sirolimus therapies to compare and understand distinctly the effectiveness and tolerability of these drugs. This will assist clinicians in making the best treatment decisions and improve the clinical prognosis of LT recipients with HCC.

关键词： Rapamycin Tacrolimus Sirolimus Immunosuppressants Hepatocellular carcinoma Liver transplantation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma:A systematic review

引用

World Journal of Gastrointestinal Oncology 2021年第11期13卷 1813-1832页

作者： Faiza Ahmed Jennifer Onwumeh-Okwundu Zeynep Yukselen Maria-Kassandra Endaya Coronel Madiha Zaidi Prathima Guntipalli Vamsi Garimella Sravya Gudapati Marc Darlene Mezidor Kim Andrews mohamad mouchli Endrit Shahini Division of Clinical and Translational Research Larkin Community HospitalSouth MiamiFL 33143United States Community Health Division University of StellenboschStellenbosch 7602South Africa College of Medicine Howard UniversityWashingtonDC 520United States College of Medicine Washington University of Health and ScienceSan PedroBelize Department of Radiology Amita Health Saint Francis HospitalEvastonIL 60202United States Department of Mathematics and Natural Sciences Prince Mohammad Bin Fahad UniversityAl Khobar 31952Saudi Arabia Department of Gastroenterology Cleveland ClinicClevelandOH 44195United States National Institute of Gastroenterology"S.de Bellis" Research HospitalCastellana Grotte(Bari)70013Italy

BACKGROUND Despite the use of current standard therapy,the prognosis of patients with unresectable hepatocellular carcinoma(HCC)is poor,with median survival times of 40 mo for intermediate HCC(Barcelona Clinic Liver Cancer[BCLC]stage B)and 6-8 mo for advanced HCC(BCLC stage C).Although patients with earlystage HCC are usually suitable for therapies with curative intention,up to 70% of patients experience relapse within 5 *** the past decade,the United States Food and Drug Administration has approved different immunogenic treatment options for advanced HCC,the most common type of liver cancer among ***,no treatment is useful in the adjuvant *** 2007,the multikinase inhibitor sorafenib has been used as a first-line targeted drug to address the increased mortality and incidence rates of ***,in 2020,the IMbrave150 trial demonstrated that combination therapy of atezolizumab(antiprogrammed death-ligand 1[PD-L1])and bevacizumab(anti-vascular endothelial growth factor[VEGF])is superior to sorafenib,a single anti-programmed death 1/PD-L1 antibody inhibitor used as an anti-cancer monotherapy for HCC *** To conduct a systematic literature review to evaluate the evidence supporting the efficacy and safety of atezolizumab/bevacizumab as preferred first-line drug therapy over the conventional sorafenib or atezolizumab monotherapies,which are used to improve survival outcomes and reduce disease progression in patients with unresectable HCC and non-decompensated liver *** A comprehensive literature review was conducted using the PubMed,Scopus,ScienceDirect,***,PubMed Central,Embase,EuropePMC,and CINAHL databases to identify studies that met the inclusion criteria using relevant MeSH *** systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and risk of bias(RoB)were assessed using the Cochrane RoB 2 tool and *** In the

关键词： Hepatic malignancy Combination systemic therapy Immunogenetic therapy Liver transplantation Barcelona clinic liver cancer Transarterial chemoembolization

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Colonoscopy surveillance for high risk polyps does not always prevent colorectal cancer

引用

World Journal of Gastroenterology 2018年第8期24卷 905-916页

作者： mohamad a mouchli Lidia Ouk Marianne R Scheitel Alisha P Chaudhry Donna Felmlee-Devine Diane E Grill Shahrooz Rashtak Panwen Wang Junwen Wang Rajeev Chaudhry Thomas C Smyrk Ann L Oberg Brooke R Druliner Lisa A Boardman Division of Gastroenterology and Hepatology Mayo Clinic Knowledge and Delivery Center Mayo Clinic Biostatistics and Bioinformatics Health Sciences Research Mayo Clinic Division of Biomedical Statistics and Informatics Health Sciences Research Mayo Clinic Biostatistics and Bioinformatics Health Science Research Center for Individualized Medicine Mayo Clinic Department of Biomedical Informatics Arizona State University Primary Care Internal Medicine Mayo Clinic Center for Innovation Mayo Clinic Department of Laboratory Medicine and Pathology Mayo Clinic

AIM To determine the frequency and risk factors for colorectal cancer(CRC) development among individuals with resected advanced adenoma(AA)/traditional serrated adenoma(TSA)/advanced sessile serrated adenoma(ASSA). METHODS Data was collected from medical records of 14663 subjects found to have AA, TSA, or ASSA at screening or surveillance colonoscopy. Patients with inflammatory bowel disease or known genetic predisposition for CRC were excluded from the study. Factors associated with CRC developing after endoscopic management of high risk polyps were calculated in 4610 such patients who had at least one surveillance colonoscopy within 10 years following the original polypectomy of the incident advanced polyp. RESULTS84/4610(1.8%) patients developed CRC at the polypectomy site within a median of 4.2 years(mean 4.89 years), and 1.2%(54/4610) developed CRC in a region distinct from the AA/TSA/ASSA resection site within a median of 5.1 years(mean 6.67 years). Approximately, 30%(25/84) of patients who developed CRC at the AA/TSA/ASSA site and 27.8%(15/54) of patients who developed CRC at another site had colonoscopy at recommended surveillance intervals. Increasing age; polyp size; male sex; right-sided location; high degree of dysplasia; higher number of polyps resected; and piecemeal removal were associated with an increased risk for CRC developmentat the same site as the index polyp. Increasing age; right-sided location; higher number of polyps resected and sessile endoscopic appearance of the index AA/TSA/ASSA were significantly associated with an increased risk for CRC development at a different site. CONCLUSION Recognition that CRC may develop following AA/TSA/ASSA removal is one step toward improving our practice efficiency and preventing a portion of CRC related morbidity and mortality.

关键词： Colon cancer Rectal Cancer Advanced adenoma Sessile serrated adenoma High risk polyps Post-polypectomy colorectal cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：